Trials / Unknown
UnknownNCT00003165
Doxorubicin in Treating Women With Advanced Breast Cancer
A Phase II Trial of PK1 in Women With Advanced Breast Cancer
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (estimated)
- Sponsor
- University of Glasgow · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different forms may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of doxorubicin in treating women with advanced metastatic breast cancer.
Detailed description
OBJECTIVES: I. Determine the antitumor activity of doxorubicin-HPMA conjugate (PK1) in women with advanced breast cancer. OUTLINE: This is an open label, multicenter study. Patients receive doxorubicin-HPMA conjugate (PK1) by intravenous infusion once every 3 weeks. Patients may receive a total of 6 courses of treatment in the absence of toxicity and progressive disease. PROJECTED ACCRUAL: 14-25 patients will be accrued for this study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | doxorubicin-HPMA conjugate |
Timeline
- Start date
- 1997-12-01
- First posted
- 2004-04-30
- Last updated
- 2013-12-19
Locations
6 sites across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00003165. Inclusion in this directory is not an endorsement.